C-QIYPaging biology, systems biology, drug development
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Assess safety and efficacy of ABBV-CLS-628 for treatment of autosomal dominant polycystic kidney disease in adults.
Randomized clinical study with intravenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks across approximately 100 sites worldwide.
ANCHOR study published on ClinicalTrials.gov, enrolling around 240 adult participants with ADPKD.
Assess safety and efficacy of ABBV-CLS-628 for treatment of adult participants with autosomal dominant polycystic kidney disease.
Randomized clinical trial with intravenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks across approximately 100 sites worldwide.
ANCHOR Study enrolling around 240 adult ADPKD participants, published on ClinicalTrials.gov on 2025-06-09.
Characterize how glucose, lipid metabolism, and NAD-related metabolic pathways change with healthy aging.
Mouse isotope-tracing study using intravenous [U-13C]-glucose across plasma, liver, gastrocnemius muscle, and brain tissues in young and old mouse strains.
2025 Aging Cell publication on effects of aging on glucose and lipid metabolism in mice.
Glucose incorporation into central carbon and amino acid metabolism remained robust during healthy aging; NAD+, NADH, and NAD+/NADH ratio were unchanged, while aging tissues showed evidence of upregulated NAD+-generating lipid metabolism reactions, particularly in brain.
Identify regulators of the integrated stress response and assay mechanistically informative ribonucleoprotein-linked phenotypes in pooled genetic screens.
CRISPR PuRification sequencing platform using pooled screening of barcoded ribonucleoprotein reporters.
2025 Nucleic Acids Research publication describing CRISPuRe-seq and ISR-mediated repression of tRNA production through mTORC1 and MAF1.
The screen found that the integrated stress response represses tRNA production under reduced protein synthesis through inhibition of mTORC1 and activation of MAF1.
Develop an investigational eIF2B activator for Vanishing White Matter disease in adult, pediatric, and infant participants.
Open-label exploratory clinical study in VWM disease plus Phase 1 clinical pharmacology studies in healthy subjects, including food-effect, drug-interaction, thorough QT, and radiolabeled mass-balance studies.
ClinicalTrials.gov lists a 2024 mass-balance study of [14C] ABBV-CLS-7262 in healthy male volunteers; Calico also lists Fosigotifator/VWM in its clinical pipeline.
A 2026 publication listed by Calico reports discovery of fosigotifator as a potent eIF2B activator with desired properties for human studies.
Evaluate fosigotifator as an investigational treatment for Vanishing White Matter disease in adult, pediatric, and infant participants.
Open-label, multiple-cohort exploratory clinical study over 201 weeks, plus healthy-volunteer pharmacokinetic, food-effect, drug-interaction, mass-balance, and QT studies of ABBV-CLS-7262.
Open-label exploratory Vanishing White Matter disease study published on ClinicalTrials.gov on 2023-03-13; related ABBV-CLS-7262 Phase 1 healthy-volunteer studies published through 2024-05-21.
Understand biology controlling aging, lifespan, and age-related disease in order to develop interventions for longer, healthier lives.
Basic biology, technology labs, advanced computing, collaborations, and translational drug development.
Ongoing research program reflected in Calico site description and 2024 Nature-linked genetics, diet, health, and longevity collaboration publication.
Assess ABBV-CLS-484 as monotherapy and in combination regimens for locally advanced or metastatic solid tumors.
Clinical dose-escalation and dose-expansion study evaluating safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy as monotherapy and in combination with a PD-1 targeting agent or VEGFR tyrosine kinase inhibitor.
Clinical study includes monotherapy dose escalation, combination dose escalation, and dose expansion in tumor types including HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced clear cell renal cell carcinoma.
Develop an oncology therapeutic program listed in Calico's pipeline.
Undisclosed therapeutic program; supplied material lists the program but does not describe intervention or trial design.
Listed in Calico pipeline materials under oncology.
Pipeline compound associated with Calico's early- and clinical-stage therapeutic development efforts.
Not disclosed in the supplied material.
Listed in the supplied site analysis as part of Calico's pipeline.
Assess safety, pharmacokinetics, pharmacodynamics, preliminary efficacy, and recommended dosing of ABBV-CLS-484 in locally advanced or metastatic tumors.
Clinical study of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or VEGFR tyrosine kinase inhibitor, including dose escalation and dose expansion cohorts.
Clinical study in locally advanced or metastatic tumors listed in public records and Calico pipeline materials.
Understand biology that controls aging and lifespan and use that knowledge to discover and develop interventions for longer, healthier lives.
Basic biology, technology labs, advanced computing, collaborations, and translational drug development focused on aging and age-related diseases.
Calico reports an expanding pipeline of early- and clinical-stage compounds targeting diseases commonly linked with aging.
Characterize how glucose, lipid, NAD+, and related metabolic pathways change with healthy aging.
Stable-isotope glucose tracing in young and old mouse strains across plasma, liver, gastrocnemius muscle, and brain tissues.
2025 Aging Cell publication: Effects of Aging on Glucose and Lipid Metabolism in Mice.
Glucose incorporation into central carbon and amino acid metabolism remained robust during healthy aging, NAD+/NADH ratios were unchanged, and aging tissues showed evidence of NAD+-regenerating lipid metabolism reactions, especially in brain.
Discover potent and orally bioavailable CD38 small molecule inhibitors.
Small-molecule drug discovery program reported in a 2026 ACS publication.
Publication titled "Discovery of Potent and Orally Bioavailable Novel Cluster of Differentiation 38 (CD38) Small Molecule Inhibitors" listed for 2026.
Discover potent, orally bioavailable CD38 small molecule inhibitors.
Small-molecule drug discovery program reported in a 2026 Calico-listed publication.
Publication listed by Calico: Discovery of Potent and Orally Bioavailable Novel Cluster of Differentiation 38 (CD38) Small Molecule Inhibitors.
The supplied title reports potent and orally bioavailable novel CD38 small molecule inhibitors; no abstract or detailed results were supplied.
Enable pooled genetic screening of mechanistically informative ribonucleoprotein phenotypes and identify regulators of integrated stress response biology.
CRISPR PuRification sequencing uses pooled screening of barcoded ribonucleoprotein reporters to link genotypes to expressed RNA barcodes.
2025 Nucleic Acids Research publication describing CRISPuRe-seq and its discovery that the integrated stress response represses tRNA production through mTORC1/MAF1 signaling.
The study found cross-talk between integrated stress response and mTOR signaling that coherently downregulates tRNA expression and protein synthesis.
Activate eIF2B to attenuate the integrated stress response and restore protein synthesis, with drug-like properties suitable for human studies.
Small-molecule prodrug discovered through medicinal chemistry optimization of ISRIB/eIF2B activator analogs to improve solubility and absorption.
Reported as currently being investigated in the clinic in a 2026 Journal of Medicinal Chemistry publication.
Fosigotifator showed significantly improved solubility versus prior ISRIB-derived analogs and was selected after a prodrug campaign.
Study relationships among genetics, diet, health, and longevity.
Research collaboration reported in a 2024 Nature publication listed in supplied filtered publications.
2024 publication: Research Collaboration Sheds New Light on the Relationship Between Genetics, Diet, Health and Longevity.
Study the relationship between genetics, diet, health and longevity.
Research collaboration reported through a 2024 Nature publication/article listed on Calico's site.
2024 publication/article listed by Calico on the relationship between genetics, diet, health and longevity.
Investigate how chronic integrated stress response contributes to dysregulated cholesterol synthesis in white matter disease.
Disease-biology research connected to integrated stress response biology and white matter disease mechanisms.
Publication listed by Calico: Chronic integrated stress response causes dysregulated cholesterol synthesis in white matter disease.
The supplied title indicates chronic integrated stress response causes dysregulated cholesterol synthesis in white matter disease.
Develop genetically encoded quantum-sensitive fluorescent protein tools for multimodal sensing and bio-imaging applications.
Directed evolution of magneto-sensitive fluorescent proteins; optically detected magnetic resonance and fluorescence magnetic-field effects in living bacterial cells.
2026 Nature publication reporting engineered MagLOV variants and sensing modalities including localization, microenvironment sensing, multiplexed imaging and lock-in detection.
MagLOV showed room-temperature optically detected magnetic resonance in living bacterial cells with signal-to-noise sufficient for single-cell detection.
Identify genetic variants, anatomical fat depots, and imaging-derived adipose phenotypes associated with disease risk.
MRI-derived phenotyping and genetic analysis of fat depots in UK Biobank, including 3D mesh-derived abdominal subcutaneous adipose tissue thickness and Mendelian randomization analyses.
2025 publications on MRI-based genetic studies of fat distribution and 3D abdominal subcutaneous adipose tissue thickness associations with disease and anthropometric factors.
Supplied abstracts report depot-specific associations with metabolic, cardiovascular, gallstone, fatty liver, thrombotic, osteoporosis, type 2 diabetes, hypertension, and incident cardiovascular disease risks.
Develop a clinical-stage oncology compound listed in Calico's pipeline.
Undisclosed oncology intervention; supplied material lists ABBV-CLS-616 under Calico's pipeline.
Listed on Calico clinical-trials pipeline page.
Enable scalable transfer of DNA regulatory sequence models to novel biological contexts for gene regulation and variant-effect analysis.
Parameter-efficient fine-tuning of supervised regulatory sequence models, demonstrated using Borzoi across bulk and single-cell RNA-seq datasets.
2026 Genome Biology publication reporting a transfer-learning framework for regulatory sequence models.
Transferred models predicted held-out gene expression changes, identified regulatory drivers in perturbation conditions, predicted cell-type-specific variant effects and aided interpretation of fine-mapped GWAS variants while reducing runtime and memory requirements.
Understand molecular drivers of phenotypic heterogeneity and cellular fate during aging.
Single-cell transcriptomics combined with longitudinal fluorescence microscopy in budding yeast, plus targeted genetic perturbations.
2026 publication describing independent aging processes and a competing hazards model in budding yeast.
The study found that rDNA instability and mitochondrial dysfunction can progress concurrently, are not necessarily mutually exclusive and may independently compete to determine cellular fate.
Characterize resistance mechanisms to WRN helicase inhibitors in microsatellite instable and mismatch-repair-deficient cancers.
Studies using the clinical candidate HRO761 and two novel inhibitors in MSI cell lines and xenograft models, with sequencing and computational structural analyses of resistance mutations.
2026 Molecular Cancer Therapeutics publication describing on-target resistance mutations to WRN helicase inhibitors.
Resistance emerged rapidly in vitro and in vivo through clustered WRN helicase-domain mutations; some mutations showed chemotype-specific resistance, suggesting next-generation inhibitor and treatment-strategy opportunities.